Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1050577Generated: November 1, 2026

Cesium carbonate → US9656988, Example 252

https://huagongshe.com/reaction/1050577

Reaction equation

Participants

RoleNameHCIDCharge
ReactantCesium carbonateHCID 10796—
ReactantBinap, (A+-)-HCID 634876—
ReactantTert-butyl 4-(4-aminophenyl)-4-methylpiperidine-1-carboxylateHCID 118115227—
Reactant3-chloro-5-((2R,3R)-2-methyl-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carbonitrileHCID 118133430—
Catalystpalladium(II) acetateHCID 167845—
Solvent1,4-DioxaneHCID 31275—
ProductUS9656988, Example 252HCID 118133432—

Reaction Conditions

Temperature115 °C

Reaction Steps

The mixture of 3-chloro-5-((2R,3R)-2-methyl-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carbonitrile (357) (100 mg, 0.60 mmol), tert-butyl 4-(4-aminophenyl)-4-methylpiperidine-1-carboxylate (287) (175 mg, 0.60 mmol), fine-powder cesium carbonate (590 mg, 1.80 mmol), Pd(OAc)2 (45 mg, 0.2 mmol), BINAP (125 mg, 0.2 mmol) in 30 mL dioxane was degassed with nitrogen stream for 3 min. It was then stirred in 115° C. bath in nitrogen atmosphere for 70 min. The mixture was cooled to RT, diluted with 120 mL EtOAc, and filtered. The filtrate was concentrated in vacuo and subjected to silica flash column using 0 to 4% MeOH in chloroform to isolate tert-butyl 4-(4-(3-cyano-6-((2R,3R)-2-methyl-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazin-2-ylamino)phenyl)-4-methylpiperidine-1-carboxylate (358). It was dissolved in 10 mL MeOH and 2 mL DMSO. To it were added fine-powder Cs2CO3 (50 mg) and then 1 mL 30% H2O2. The mixture was stirred at RT for 30 min, diluted with 10 mL MeCN, stirred for 5 min, and concentrated on rotavap. The residue was diluted with 150 mL EtOAc, washed with water ×3, dried, concentrated in vacuo, and subjected to silica flash column using 0 to 4% MeOH in DCM to isolate tert-butyl 4-(4-(3-carbamoyl-6-((2R,3R)-2-methyl-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazin-2-ylamino)phenyl)-4-methylpiperidine-1-carboxylate (359). It was treated with 2:1 DCM/TFA (12 mL/6 mL) at RT for 30 min. The mixture was concentrated in vacuo. One third of the residue was dissolved in MeOH/water and directly subjected to reverse phase prep HPLC using 5 mM HCl (aq) and neat MeCN as mobile phases to isolate 5-((2R,3R)-2-methyl-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)-3-(4-(4-methylpiperidin-4-yl)phenylamino)pyrazine-2-carboxamide (360) as HCl salt (65 mg). LC-MS (ESI): m/z (M+1) 507.8. UV: λ=268, 277, 306, 336, 372 nm. Proton NMR (CD3OD): δ 7.68 (2H, d, J=9.0 Hz), 7.62 (1H, s), 7.35 (2H, d, J=8.5 Hz), 5.11 (1H, m), 4.28 (1H, m), 3.89 (1H, m), 3.53 (2H, m), 3.38 (2H, m), 3.30 (2H, m), 3.06 (3H, m), 2.81 (3H, s), 2.42 (2H, m), 2.03 (1H, m), 1.95 (3H, m), 1.83 (1H, m), 1.68 (1H, m), 1.31 (3H, s), 1.21 (3H, d, J=7.0 Hz) ppm.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09382246B2
Source datasetuspto-grants-2016_07
ORD IDord-fc0e8def1d864f148e918095e22267ed
Source noteuspto-grants-2016_07